Overview

The Effect of SAAE on Ventricular Remodeling in PA Patients

Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
0
Participant gender:
All
Summary
The study aims to assess the effect of superselective adrenal arterial embolization on ventricular remodeling in primary aldosteronism without lateralized aldosterone secretion by comparing it with spironolactone therapy.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Second Affiliated Hospital of Nanchang University
Treatments:
Spironolactone
Criteria
Inclusion Criteria:

- (1) Age 18-60 years old, regardless of gender;

- (2) Blood pressure conditions meet one of the following: 1) Office blood pressure ≥
140/90mmHg; 2) Ambulatory blood pressure monitoring whole day blood pressure > 130/80
mmHg or daytime blood pressure > 135/85 mmHg;

- (3) After strict drug elution, it met the diagnostic criteria of primary
aldosteronism, and bilateral primary aldosteronism was confirmed by adrenal venous
sampling;

- (4) No surgical intent or contraindication to surgery and willing to undergo
pharmacological treatment or percutaneous superselective adrenal artery embolization;

- (5) The patient or his/her legal representative shall sign the written informed
consent approved by the ethics committee before the screening.

Exclusion Criteria:

- (1) Primary hypertension or secondary hypertension with other causes;

- (2) A woman who is pregnant or lactating, or has a birth plan for the next year;

- (3) There are serious organic diseases, especially liver and kidney
dysfunction(eGFR<45 mL/min/1.73 m2);

- (4) Severe allergy to contrast medium;

- (5) Other serious organic diseases, life expectancy < 12 months;

- (6) Adrenal CT showed adenoma.;

- (7) Patients are enrolled or want to participate in other clinical studies. During the
enrollment study, the results of this study will be affected.